<DOC>
	<DOCNO>NCT02633202</DOCNO>
	<brief_summary>Currently , concurrent chemoradiotherapy with/without sequential chemotherapy standard treatment modality intermediate risk NPC ( stage II T3N0M0 ) accord National Comprehensive Cancer Network guideline . However recommendation base evidence two-dimensional conventional radiotherapy ( 2DCRT ) era . The introduction intensity-modulated radiotherapy ( IMRT ) NPC treatment bring substantial well treatment outcomes 2DCRT . It question whether additional concurrent chemotherapy still necessary intermediate risk NPC within excellent framework IMRT . Thus , investigator jointly conduct first non-inferior randomize trial determine value concurrent chemotherapy cisplatin intermediate risk NPC patient treat IMRT . Given result clinical study mention , investigator decide adopt concurrent regimen cisplatin 100 mg/m2 day 1 , 22 , 43</brief_summary>
	<brief_title>Concurrent Chemotherapy Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era</brief_title>
	<detailed_description>Currently , concurrent chemoradiotherapy with/without sequential chemotherapy standard treatment modality intermediate risk NPC ( stage II T3N0M0 ) accord National Comprehensive Cancer Network guideline . However recommendation base evidence two-dimensional conventional radiotherapy ( 2DCRT ) era . The introduction intensity-modulated radiotherapy ( IMRT ) NPC treatment bring substantial well treatment outcomes 2DCRT . It question whether additional concurrent chemotherapy still necessary intermediate risk NPC within excellent framework IMRT . Thus , investigator jointly conduct first non-inferior randomize trial determine value concurrent chemotherapy cisplatin intermediate risk NPC patient treat IMRT . Given result clinical study mention , investigator decide adopt concurrent regimen cisplatin 100 mg/m2 day 1 , 22 , 43</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients newly histologically confirm nonkeratinizing ( accord WHO histologically type . Tumor stag T12N1/T23N0 ( accord 7th AJCC edition ) . No evidence distant metastasis ( M0 ) . Satisfactory performance status : Karnofsky scale ( KPS ) ≥ 70 . Adequate marrow : leucocyte count ≥ 4000/μL , hemoglobin ≥ 120g/L male , ≥ 120g/L female , platelet count ≥ 100000/μL . Normal liver function test : Alanine Aminotransferase ( ALT ) , Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤ 2.5×ULN , bilirubin ≤ ULN . Adequate renal function : creatinine clearance ≥ 60 ml/min . Patients must inform investigational nature study give write informed consent . Neck lymph node extracapsular spread . Maximal axial diameter neck lymph node ≥30mm , positive neck lymph node level IV and/or Vb . Pretreatment plasma EBV DNA level ≥4000 copy/ml . WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma . Age &gt; 65 &lt; 18 . Treatment palliative intent . Prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer . Pregnancy lactation ( consider pregnancy test woman childbearing age emphasize effective contraception treatment period ) . History previous RT ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . Prior chemotherapy surgery ( except diagnostic ) primary tumor node . Any severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Nasopharyngeal carcinoma</keyword>
	<keyword>Concurrent chemoradiotherapy</keyword>
	<keyword>intermediate risk</keyword>
	<keyword>intensity-modulated radiotherapy</keyword>
</DOC>